Abortion drug rulings spur drugmaker worries about precedent
Critics of a court decision banning an abortion drug say the ruling undermines the FDA's ability to regulate the drug industry.
Stay updated with breaking news from William Schultz. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Critics of a court decision banning an abortion drug say the ruling undermines the FDA's ability to regulate the drug industry.
Senior executives of more than 400 pharmaceutical and biotech companies and investment firms on Monday issued a scorching condemnation of a ruling by a federal judge that invalidated the Food and Drug Administration’s 23-year-old approval of the abortion pill mifepristone, and they called for the decision to be reversed.
Democrats are pressuring the 19 Biden-district Republicans to sign onto a bill countering the ruling.
Kacsmaryk’s decision could fling wide the floodgates to those seeking to challenge the FDA’s approval in an attempt to get certain drugs removed from the market.
The ramifications from Friday’s decision for the FDA and the drug industry could be felt for decades.